• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Studies on CGRP receptor subtypes and their specific intracellular signaling pathways in the periodontal tissue

Research Project

Project/Area Number 12671803
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Functional basic dentistry
Research InstitutionNiigata University

Principal Investigator

KAWASE Tomoyuki  Graduate School of Medical and Dental Sciences, Niigata University, Associate Professor, 大学院・医歯学総合研究科, 助教授 (90191999)

Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2001: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2000: ¥2,400,000 (Direct Cost: ¥2,400,000)
KeywordsCGRP / Receptor / Phosphorylation / cAMP / MAPK / Calcium
Research Abstract

Based on the published data about 3-D configuration of CGRP, we have attempted to produce some CGRP fragments and performed bioassay with those new peptides. However, we could not particularly find any bioactive peptides.
1) Production of CGRP fragments and screening - In addition to commercially available human CGRP_<1-37>, CGRP_<8-37>, CGRP_<19-37>, CGRP_<22-37> and [Cys(Acm)^<2,7>]-CGRP, we have produced CGRP_<1-12>, reverse-CGRP_<1-8> and reverse-CGRP_<1-14>. On screening with cAMP production and other indeces, we have found that CGRP_<8-37>, CGRP_<22-37> and [Cys(Acm)^<2,7>]-CGRP have substantial agonistic or antagonistic action. 2) Effects of bioactive CGRP fragments on intracelllar signaling pathways - In osteoblastic MG63 cells, CGRP_<8-37> potently anta gonized CGRP_<1-37> action in cAMP production. CGRP_<22-37>, also had a weak antagonistic action. [Cys(Acm)^<2,7>]-CGRP showed both a medium antagonistic and a weak agonistic action. Similar results were obtained in either gingival fibroblastic Gin-1 or oral epithelial SCC25 cells. 3) Binding affinity of bioactive CGRP fragments - Fluoro-CGRP bound to its receptors in a concentration-dependent fashion, and its binding was specifically replaced with CGRP_<8-37>, but not clearly with [Cys(Acm)^<2,7>]-CGRP. 4) Effects of CGRP fragments on cell proliferation - Any CGRP fragments produced here failed to reproducibly influence the proliferation, but only CGRP_<1-37> weakly stimulated Gin-1 proliferation. 5) Effects of CGRP fragments on cell apoptosis - Any CGRP fragments did not apparently induce apoptosis in any cell types used here. 6) Expression of CGRP receptor subtypes in periodontal tissues - Expression of both CRLR and RAMP-I proteins were detected using those specific antibodies either in periodontal tissues or in any cell types used here.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (3 results)

All Other

All Publications (3 results)

  • [Publications] Kawase, Tomoyuki: "Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclar accumulation of smad2 In both Oral epithelial and fibroblastic human cells"Journal of Periodontal Research. 36. 367-376 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kawase, Tomoyuki: "Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells."Journal of Periodontal Research. 36. 367-376 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kawase, Tomoyuki: "Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclar accumulation of smad2 In both oral epithelial and fibroblastic human cells"Journal of Periodontal Research. 36. 367-376 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi